AstraZeneca Pharma India has launched Selumetinib 10 mg and 25 mg capsule (Koselugo) in India. Selumetinib (Koselugo) is indicated for treatment of Pediatric patients 3 years of age and older with neurofibromatosis type 1 (NF1) and who have symptomatic, inoperable plexiform neurofibromas (PN).
Earlier, the company had received Import and Market Permission in Form CT-20 from the Drugs Controller General of India for Selumetinib (Koselugo).
AstraZeneca Pharma India is a global biopharmaceutical company. The company is engaged in the discovery, development and commercialization of medicines for core areas of healthcare, including cardiovascular/metabolic disease, cancer and respiratory, inflammatory and autoimmune disease. The company operates through two segments Healthcare and Clinical Trial.
